Xia Yang1, Xin Ye1, Zhengyu Lin2, Yong Jin3, Kaixian Zhang4, Yuting Dong5, Guohua Yu6, Haipeng Ren6, Weijun Fan7, Jin Chen2, Qingfeng Lin2, Guanghui Huang1, Zhigang Wei1, Yang Ni1, Wenhong Li1, Xiaoying Han1, Min Meng1, Jiao Wang1, Yuliang Li8. 1. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. 2. Department of Interventional Therapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. 3. Department of Interventional Therapy, The Second Affiliated Hospital of Soochow University, Suzhou, China. 4. Department of Oncology, Teng Zhou Central People's Hospital Affiliated to Jining Medical College, Tengzhou, China. 5. Department of Oncology, Dezhou City People's Hospital, Dezhou, China. 6. Department of Oncology, Weifang People's Hospital Affiliated to Weifang Medical College, Weifang, China. 7. Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou, China. 8. Interventional Treatment Center, The Second Hospital Affiliated to Shandong University, Jinan, China.
Abstract
PURPOSE: The purpose of the study is to retrospectively evaluate the safety and efficacy of microwave ablation (MWA) for the treatment of ground-glass opacity (GGO)-lung adenocarcinoma. MATERIALS AND METHODS: From December 2013 to June 2017, a total of 51 patients (22 males and 29 females, mean age of 69.4 ± 10.1 years) were included in this study, with 51 lung adenocarcinoma lesions showing GGO (mean long-axis diameter of 18.7 ± 6.05 mm). They received a total of 52 sessions of percutaneous computed tomography-guided (CT-guided) MWA. First, lung adenocarcinoma with GGO was histologically defined by needle biopsy under the guidance of CT. Second, the efficacy of CT-guided MWA was analyzed, including the feasibility, safety, 3 years local progression-free survival (LPFS), 3 years disease-specific survival, and 3 years overall survival (OS). Final, complications after MWA were also summarized. RESULTS: The technical success rate was 100%, without MWA procedure-related death. At the median follow-up period (27.02, range: 7-45 months), the rates of 3 years LPFS, cancer-specific survival, and OS were 98%, 100%, and 96%, respectively. The complications after MWA included pneumothorax (48.1%, 25/52), hemoptysis (28.8%, 14/52), pleural effusion (23.1%, 12/52), and pulmonary infection (7.7%, 4/52). CONCLUSIONS: CT-guided percutaneous MWA was a feasible, safe, and effective therapeutic approach for treating GGO-lung adenocarcinoma.
PURPOSE: The purpose of the study is to retrospectively evaluate the safety and efficacy of microwave ablation (MWA) for the treatment of ground-glass opacity (GGO)-lung adenocarcinoma. MATERIALS AND METHODS: From December 2013 to June 2017, a total of 51 patients (22 males and 29 females, mean age of 69.4 ± 10.1 years) were included in this study, with 51 lung adenocarcinoma lesions showing GGO (mean long-axis diameter of 18.7 ± 6.05 mm). They received a total of 52 sessions of percutaneous computed tomography-guided (CT-guided) MWA. First, lung adenocarcinoma with GGO was histologically defined by needle biopsy under the guidance of CT. Second, the efficacy of CT-guided MWA was analyzed, including the feasibility, safety, 3 years local progression-free survival (LPFS), 3 years disease-specific survival, and 3 years overall survival (OS). Final, complications after MWA were also summarized. RESULTS: The technical success rate was 100%, without MWA procedure-related death. At the median follow-up period (27.02, range: 7-45 months), the rates of 3 years LPFS, cancer-specific survival, and OS were 98%, 100%, and 96%, respectively. The complications after MWA included pneumothorax (48.1%, 25/52), hemoptysis (28.8%, 14/52), pleural effusion (23.1%, 12/52), and pulmonary infection (7.7%, 4/52). CONCLUSIONS: CT-guided percutaneous MWA was a feasible, safe, and effective therapeutic approach for treating GGO-lung adenocarcinoma.